Semaglutide: The Newest Once-Weekly GLP-1 RA for Type 2 Diabetes.
Rhianna M TuchschererAngela M ThompsonJennifer M TrujilloPublished in: The Annals of pharmacotherapy (2018)
Semaglutide is an appealing option for the treatment of T2D as a once-weekly GLP-1 RA with established glycemic, CV, and weight benefits.